HK2 and neoplasm: Benitrobenrazide (BNBZ) and 2-DG, a direct targeted inhibitor of HK2, has been found to inhibit glycolysis in tumor cells in vivo and in vitro; Moreover, oral administration of BNBZ could significantly inhibit tumor growth [245, 246].